From our partner Irene Tarragó

This month of March we commemorate International Women’s Day, on the 8th, and, a little later, on the 26th, World Epilepsy Day.

Taking advantage of the fact that this month these two dates are commemorated, I would like, first of all, to congratulate all the women and urge them and the men who think that equality is a right, to continue fighting as until now, without giving up, because we are living in times turbulent and we cannot allow ourselves to take a step back in the search and achievement of equal rights. And, secondly, tell you about the special relationship that women have with epilepsy.

Women, simply because they are women, have to be more careful with treatment and pay more attention to symptoms than men.

Women experience different hormonal changes throughout their lives, so epilepsy treatment may vary depending on the stage they are in.

Menstruation, contraceptives, pregnancy and menopause are circumstances that can influence the control of epilepsy.

Some women may notice that there is a relationship between their menstrual cycles and the frequency of their attacks. It is called catamenial epilepsy. There is a greater chance of having a crisis, either while the body is ovulating or in the first months of menstruation.

Regarding contraceptives, the possible interactions of this type of medication and antiepileptic treatment must be taken into account, since it may happen that both lose effect when combined.

One of the most delicate moments of treatment for a woman with epilepsy is pregnancy. At that moment, the woman asks herself many questions, such as: Can my son inherit epilepsy? Will I be able to continue with my treatment? Will I be able to breastfeed him? She has to resolve all of them and many more with her neurologist.

During menopause and its hormonal changes, the frequency of attacks may vary in some women. Additionally, during this period, women are more likely to have osteoporosis and some epilepsy medications can worsen osteoporosis and vice versa.

It is therefore necessary that in the design of medications for the treatment of epilepsy, the peculiar idiosyncrasies of women be taken into account and it is also necessary that health professionals have exact knowledge of the repercussions that a drug antiepileptic can have in a pregnant woman or in a woman who is already in menopause.

Women experience different hormonal changes throughout their lives, so epilepsy treatment may vary depending on the stage they are in.

Research must continue in the field of epilepsy, since there are still 30% of people diagnosed who cannot control their seizures in any way, not even with surgery, so research is essential.

Leave a Reply

Open chat
Contact with us now
Chat with Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.